<DOC>
	<DOCNO>NCT00566761</DOCNO>
	<brief_summary>Treatment macular edema secondary central retinal vein occlusion effective combine therapy bevacizumab triamcinolone bevacizumab alone .</brief_summary>
	<brief_title>Treatment Bevacizumab Triamcinolone Treatment Macular Edema Secondary CRVO</brief_title>
	<detailed_description>Comparison two group different treatment registration outcome BCVA complication</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Macular edema secondary central retinal vein occlusion BCVA worse 20/40 Central macular &gt; 250 mc OCT Diabetic retinopathy retinopathy Media opacity allow follow steroid responder diagnose glaucoma IOP &gt; 21 mmHg</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Macular edema</keyword>
	<keyword>central retinal vein occlusion</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>triamcinolone</keyword>
</DOC>